![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication March 31, 2006.
Revised June 1, 2006.
Accepted for publication June 1, 2006.
Propranolol is a non-selective beta-adrenergic blocker used as a racemic mixture in the treatment of hypertension, cardiac arrhythmias, and angina pectoris. For study of the stereoselective glucuronidation of this drug, the two propranolol glucuronide diastereomers were biosynthesized, purified, and characterized. A screen of 15 recombinant human UDP-glucuronosyltransferases (UGTs) indicated that only a few isoforms catalyze propranolol glucuronidation. Analysis of UGT2B4 and UGT2B7 revealed no significant stereoselectivity, but these two enzymes differed in glucuronidation kinetics. The glucuronidation kinetics of R-propranolol by UGT2B4 exhibited a sigmoid curve, whereas the glucuronidation of the same substrate by UGT2B7 was inhibited by substrate concentrations above 1mM. Among the UGTs of subfamily 1A, UGT1A9 and UGT1A10 displayed high and, surprisingly, opposite stereoselectivity in the glucuronidation of propranolol enantiomers. UGT1A9 glucuronidated S-propranolol much faster than R-propranolol, whereas UGT1A10 exhibited the opposite enantiomer preference. Nonetheless, the Km values for the two enantiomers, both for UGT1A9 and for UGT1A10, were in the same range, suggesting similar affinities for the two enantiomers. Unlike UGT1A9, the expression of UGT1A10 is extrahepatic. Hence, the reverse stereoselectivity of these two UGTs may signify specific differences in the glucuronidation of propranolol enantiomers between intestine and liver microsomes. Subsequent experiments confirmed this hypothesis: human liver microsomes glucuronidated S-propranolol faster than R-propranolol, whereas human intestine microsomes glucuronidated S-propranolol faster. These findings suggest a contribution of intestinal UGTs to drug metabolism, at least for UGT1A10 substrates.
Key words:
glucuronidation, HPLC, phase II drug metabolism, structure-activity relationships, UDP glucuronyltransferases
This article has been cited by other articles:
|
|
 |
|
  K. Itaaho, P. I. Mackenzie, S.-i. Ikushiro, J. O. Miners, and M. Finel The Configuration of the 17-Hydroxy Group Variably Influences the Glucuronidation of {beta}-Estradiol and Epiestradiol by Human UDP-Glucuronosyltransferases Drug Metab. Dispos., November 1, 2008; 36(11): 2307 - 2315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. P. Kanebratt and T. B. Andersson Evaluation of HepaRG Cells as an in Vitro Model for Human Drug Metabolism Studies Drug Metab. Dispos., July 1, 2008; 36(7): 1444 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ramirez, W. Liu, S. Mirkov, A. A. Desai, P. Chen, S. Das, F. Innocenti, and M. J. Ratain Lack of Association between Common Polymorphisms in UGT1A9 and Gene Expression and Activity Drug Metab. Dispos., December 1, 2007; 35(12): 2149 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nakajima, H. Yamanaka, R. Fujiwara, M. Katoh, and T. Yokoi Stereoselective Glucuronidation of 5-(4'-Hydroxyphenyl)-5-phenylhydantoin by Human UDP-Glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: Effects of UGT-UGT Interactions Drug Metab. Dispos., September 1, 2007; 35(9): 1679 - 1686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mano, T. Usui, and H. Kamimura Predominant Contribution of UDP-Glucuronosyltransferase 2B7 in the Glucuronidation of Racemic Flurbiprofen in the Human Liver Drug Metab. Dispos., July 1, 2007; 35(7): 1182 - 1187. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
